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Background
The rabies virus belongs to the genus Lyssavirus from the
Rhabdoviridae family and is widely distributed in nature
infecting mammals. Upon infection it can be transmitted
to animals or humans and leads to a fatal disease that
nowadays has no treatment. Vaccines are commercially
available and prevent the disease in animals and humans.
Protocols for human or veterinarian vaccine manufactur-
ing evolved from animal tissue homogenates to cell cul-
ture technology and today recombinant viral proteins and
DNA vaccines are under investigation. The evidence that
rabies virus infects and can cause disease in animals and
humans, being neutralized by an immune response
mounted by very similar vaccines opens a great possibility
of testing new vaccines first in experimental animals prior
to use in humans [1].
Results
Recombinant rabies vírus glycoprotein (rGPV) was
expressed in Drosophila melanogaster Schneider 2 (S2)
cells. The cDNA encoding the GPV gene was cloned in
expression plasmids under the control of the inducible
metallothionein promoter (Mt) or the constitutive actin
promoter (Ac). These were alternatively co-transfected
into S2 cells together with a hygromycin selection plas-
mid. Selected S2 cell populations (S2MtGPV or S2AcGPV)
had a decreased ability to grow and consume substrates,
when compared to the non transfected cells (S2). They
were shown, by PCR, to express the GPV gene and mRNA
as well as, by immunoblotting, to synthesize the rGPV in
its expected molecular weight of 65 kDa. ELISA kinetic
studies showed the rGPV expression in cell lysates and
supernatants attaining concentrations ranging from 150
to 300 μg of rGPV/L. By flow cytometry analysis, about
30% of the cells in these populations were shown to
express the rGPV in their membrane. Cell populations
selected by limiting dilution expressed higher rGPV yields.
Mice immunized with S2MtGPV or S2AcGPV derived
rGPV were capable of mounting a protective immune
response characterized by the synthesis of antibodies
reacting against the rabies virus. Immunization led to pro-
tection against rabies virus experimental infection in chal-
lenge studies.
Conclusion
The data presented here show that S2 cells are suitable
hosts for the rGPV expression allowing its synthesis in a
high degree of physical and biological integrity.
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